Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02352558 · ClinicalTrials.gov registry record · Phase 1
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02352558: Completed Phase 1 study, sponsored by Sumitomo Pharma America.
NCT02352558 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 15 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02352558, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a multicenter, open label, Phase 1 dose-escalation study of BBI608 administered to patients with relapsed, refractory hematologic malignancies, including multiple myeloma, lymphoma, and others.
Interventions
- DRUG Dexamethasone
- DRUG Ibrutinib
- DRUG Bortezomib
- DRUG Imatinib
- DRUG BBI608
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-05 |
| Est. Completion | 2019-05-16 |
| Phase | Phase 1 |
What the finished NCT02352558 record still lists
NCT02352558 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 5 interventions - of which Dexamethasone is the first listed.
NCT02352558 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02352558 about?
NCT02352558 is a clinical study titled "A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies". This is a multicenter, open label, Phase 1 dose-escalation study of BBI608 administered to patients with relapsed, refractory hematologic malignancies, including multiple myeloma, lymphoma, and others.
What is the current status of trial NCT02352558?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2015-05. Estimated completion is 2019-05-16.
What interventions are being tested in trial NCT02352558?
The interventions under investigation include: Dexamethasone (DRUG), Ibrutinib (DRUG), Bortezomib (DRUG), Imatinib (DRUG), BBI608 (DRUG).
Who is sponsoring clinical trial NCT02352558?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02352558's enrollment target sits among peer trials
15 1798th of 2000 higher than 157 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia